“…Hsin-Wei Liao, 1,2 Jung-Mao Hsu, 1 Weiya Xia, 1 Hung-Ling Wang, 3 Ying-Nai Wang, 1,3,4 Wei-Chao Chang, 3 Stefan T. Arold, 5,6 Chao-Kai Chou, 1,3 Pei-Hsiang Tsou, 1 Hirohito Yamaguchi, 1 Yueh-Fu Fang, 1,7 Hong-Jen Lee, 1,2 Heng-Huan Lee, 1 Shyh-Kuan Tai, 8 Mhu-Hwa Yang, 9 Maria P. Morelli, 10 Malabika Sen, 11 John E. Ladbury, 5,12 Chung-Hsuan Chen, 13 Jennifer R. Grandis, 11,14 Scott Kopetz, 10 and Mien-Chie Hung ing activation of HER2 or MET signaling, mutation of PIK3CA and BRAF, or expression status of PTEN, but retrospective analyses revealed inconsistent and controversial findings (16). So far, the most accepted predictive marker for poor cetuximab response is mutant KRAS status, due to its association with poor survival rate under cetuximab treatment in colorectal cancer clinical trials (17)(18)(19)(20).…”